Clinical Report: Patterns of Spread in Ocular Melanoma

Overview

A retrospective study of 167 patients with conjunctival malignant melanoma revealed that 25% developed metastatic disease over a mean follow-up of 78 months. Tumor location and stage significantly influenced metastatic risk, with cT2 tumors showing higher rates of spread compared to cT1 tumors.

Background

Ocular melanoma, particularly conjunctival melanoma, poses significant treatment challenges due to its potential for metastasis. Understanding the patterns of spread is crucial for improving patient outcomes and guiding surveillance strategies. This study provides insights into the relationship between tumor characteristics and metastatic progression.

Data Highlights

Key Findings

• 25% of patients developed metastases during long-term follow-up.
• Local recurrence occurred in 47% of patients at a mean of 42 months.
• cT2 tumors were associated with higher metastatic risk compared to cT1 tumors.
• Adjuvant therapy reduced the risk of systemic spread in pT1 tumors.
• Ruthenium-106 brachytherapy was linked to lower rates of hematogenous metastasis.
• Patterns of spread followed a sequential course, with local recurrence strongly associated with distant metastasis.

Clinical Implications

Discuss the benefits of adjuvant therapy in pT1 tumors to mitigate systemic spread.

Conclusion

This study enhances the understanding of metastatic patterns in conjunctival melanoma, providing a foundation for improved risk stratification and management strategies in affected patients.

References

1. BMJ Open Ophthalmology, 2023 -- Patterns of Spread in Ocular Melanoma
2. Modeling the Genetics of Uveal Melanoma, The Ophthalmologist, 2026
3. Approaches to Treating Liver Metastases Arising from Uveal Melanoma, BJS, 2023
4. A Shift in Strategy for Ocular Melanoma, Retinal Physician, 2025
5. Uveal melanoma: ESMO–EURACAN Clinical Practice Guideline, ScienceDirect, 2026
6. FDA approves tebentafusp-tebn for unresectable or metastatic uveal melanoma, FDA, 2023
7. Retinal Physician — Ocular Tumor Masquerade Syndromes
8. Conjunctival Melanoma: A Clinical Review and Update
9. Uveal melanoma: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up - ScienceDirect
10. FDA approves tebentafusp-tebn for unresectable or metastatic uveal melanoma | FDA